(479) a Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Evaluate the Safety and Efficacy of Naldemedine in Patients With Chronic Non-Cancer Pain and Opioid-Induced Bowel Dysfunction
Journal of Pain - United States
doi 10.1016/j.jpain.2016.01.456
Full Text
Open PDFAbstract
Available in full text
Date
April 1, 2016
Authors
Publisher
Elsevier BV